Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Y0SY
|
|||
Former ID |
DIB005001
|
|||
Drug Name |
E-3620
|
|||
Indication | Gastric motility disorder [ICD-11: DA21; ICD-10: K22.4] | Discontinued in Phase 2 | [1] | |
Company |
Eisai Co Ltd
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H27Cl2N3O2
|
|||
Canonical SMILES |
CC#CC(C)OC1=CC(=C(C=C1C(=O)NC2CC3CCC(C2)N3C)Cl)N.Cl
|
|||
InChI |
1S/C20H26ClN3O2.ClH/c1-4-5-12(2)26-19-11-18(22)17(21)10-16(19)20(25)23-13-8-14-6-7-15(9-13)24(14)3;/h10-15H,6-9,22H2,1-3H3,(H,23,25);1H/t12-,13?,14-,15+;/m0./s1
|
|||
InChIKey |
GMHMNKHDLXRRGF-LZMJSSQSSA-N
|
|||
CAS Number |
CAS 151213-86-4
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | 5-HT 3 receptor (5HT3R) | Target Info | Modulator | [2] |
5-HT 4 receptor (HTR4) | Target Info | Modulator | [2] | |
KEGG Pathway | Calcium signaling pathway | |||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Serotonergic synapse | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
5HT4 type receptor mediated signaling pathway | ||||
Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | |||
Reactome | Serotonin receptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004004) | |||
REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.